The noradrenergic symptom cluster: Clinical expression and neuropharmacology

Neuropsychiatric Disease and Treatment

Volumn 7, Issue SUPPL., 2011, Pages 15-20

  Blier, Pierre ^a   Briley, Mike ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b NeuroBiz Consulting and Communication   (France)

Author keywords

Dopamine; Norepinephrine; Norepinephrine paradox; Residual symptoms; Serotonin

Indexed keywords

ANTIDEPRESSANT AGENT; ATOMOXETINE; CITALOPRAM; DOPAMINE; DULOXETINE; ESCITALOPRAM; FENCLONINE; FLUOXETINE; MILNACIPRAN; NORADRENALIN; REBOXETINE; SEROTONIN; SEROTONIN 2A AGONIST; SEROTONIN 2C AGONIST; SEROTONIN UPTAKE INHIBITOR;

APATHY; ARTICLE; COGNITION; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG INHIBITION; DRUG SAFETY; FATIGUE; HAMILTON SCALE; HUMAN; LONG TERM CARE; MAJOR DEPRESSION; NEUROMODULATION; NEUROPHARMACOLOGY; NONHUMAN; NORADRENERGIC SYSTEM; PROTEIN INTERACTION; QUALITY OF LIFE;

EID: 80155189205     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S19613     Document Type: Article

References (37)

1. Stahl SM. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 3rd ed. Cambridge, UK: Cambridge University Press; 2008.
2. Nutt D, Demyttenaere K, Janka Z, et al. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. J Psychopharmacol. 2007;21:461-471.
3. Trivedi MH, Hollander E, Nutt D, Blier P. Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression. J Clin Psychiatry. 2008;69:246-258.
4. Kurian BT, Greer TL, Trivedi MH. Strategies to enhance the therapeutic efficacy of antidepressants: targeting residual symptoms. Expert Rev Neurother. 2009;9:975-984.
5. Conradi HJ, Ormel J, de Jonge P. Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study. Psychol Med. 2011. In press.
6. Nierenberg AA, Keefe BR, Leslie VC, et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry. 1999;60:221-225.
7. Dremencov E, El Mansari M, Blier P. Noradrenergic augmentation of escitalopram response by risperidone: electrophysiologic studies in the rat brain. Biol Psychiatry. 2007;61:671-678.
8. Haddjeri N, de Montigny C, Blier P. Modulation of the f iring activity of noradrenergic neurones in the rat locus coeruleus by the 5-hydroxtryptamine system. Br J Pharmacol. 1997;120:865-875.
9. Szabo ST, de Montigny C, Blier P. Progressive attenuation of the firing activity of locus coeruleus noradrenergic neurons by sustained administration of selective serotonin reuptake inhibitors. Int J Neuropsychopharmacol. 2000;3:1-11.
10. Kawahara Y, Kawahara H, Kaneko F, Tanaka M. Long-term administration of citalopram reduces basal and stress-induced extracellular noradrenaline levels in rat brain. Psychopharmacology (Berl). 2007;194:73-81.
11. Guiard BP, El Mansari M, Merali Z, Blier P. Functional interactions between dopamine, serotonin and norepinephrine neurons: an in-vivo electrophysiological study in rats with monoaminergic lesions. Int J Neuropsychopharmacol. 2008;11:625-639.
12. Moret C, Charveron M, Finberg JP, Couzinier JP, Briley M. Biochemical profile of midalcipran (F 2207), 1-phenyl-1-diethylaminocarbonyl- 2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug. Neuropharmacology. 1985;24:1211-1219.
13. Koch S, Hemrick-Luecke SK, Thompson LK, et al. Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. Neuropharmacology. 2003;45:935-944.
14. Mongeau R, Weiss M, de Montigny C, Blier P. Effect of acute, short- and long-term milnacipran administration on rat locus coeruleus noradrenergic and dorsal raphe serotonergic neurons. Neuropharmacology. 1998;37:905-918.
15. Moret C, Briley M. Effects of milnacipran and pindolol on extracellular noradrenaline and serotonin levels in guinea pig hypothalamus. J Neurochem. 1997;69:815-822.
16. Kitaichi Y, Inoue T, Izumi T, Nakagawa S, Kato A, Koyama T. Subchronic milnacipran treatment increases basal extracellular noradrenaline concentrations in the medial prefrontal cortex of rats. Eur J Pharmacol. 2005;520:37-42.
17. Kitaichi Y, Inoue T, Nakagawa S, Izumi T, Koyama T. Effect of milnacipran on extracellular monoamine concentrations in the medial prefrontal cortex of rats pre-treated with lithium. Eur J Pharmacol. 2005;516:219-226.
18. Raiteri M, Del Carmine R, Bertollini A, Levi G. Effect of sympathomimetic amines on the synaptosomal transport of noradrenaline, dopamine and 5-hydroxytryptamine. Eur J Pharmacol. 1977;41:133-143.
19. Sesack SR, Hawrylak VA, Matus C, Guido MA, Levey AI. Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter. J Neurosci. 1998;18:2697-2708.
20. Yamamoto BK, Novotney S. Regulation of extracellular dopamine by the norepinephrine transporter. J Neurochem. 1998;71:274-280.
21. Devoto P, Flore G, Pani L, Gessa GL. Evidence for co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex. Mol Psychiatry. 2001;6:657-664.
22. Linnér L, Endersz H, Ohman D, Bengtsson F, Schalling M, Svensson TH. Reboxetine modulates the firing pattern of dopamine cells in the ventral tegmental area and selectively increases dopamine availability in the prefrontal cortex. J Pharmacol Exp Ther. 2001;297:540-546.
23. Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002;27:699-711.
24. Herrera-Guzmán I, Gudayol-Ferré E, Herrera-Abarca JE, et al. Major Depressive Disorder in recovery and neuropsychological functioning: effects of selective serotonin reuptake inhibitor and dual inhibitor depression treatments on residual cognitive deficits in patients with Major Depressive Disorder in recovery. J Affect Disord. 2010;123: 341-350.
25. Itoi K, Sugimoto N. The brainstem noradrenergic systems in stress, anxiety and depression. J Neuroendocrinol. 2010;22:355-361.
26. Hains AB, Arnsten AF. Molecular mechanisms of stress-induced prefrontal cortical impairment: implications for mental illness. Learn Mem. 2008;15:551-564.
27. Stahl SM, Grady MM, Moret C, Briley M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr. 2005;10:732-747.
28. Moojen VK, Martins MR, Reinke A, et al. Effects of milnacipran in animal models of anxiety and memory. Neurochem Res. 2006;31: 571-577.
29. Selitskii GV, Kaprin AD, Izvozchikov SB, Bolotov AV, Troshina AV. Milnacipran (ixel) in the treatment of anxiodepressive and sexual disorders in patients with noninflammatory syndrome of chronic pelvic pain. Ter Arkh. 2007;79:81-84.
30. Gama CS, Zanatto VC, Picon F, Lobato MI, Belmonte-de-Abreu PS. Efficacy of milnacipran in treating anxiety symptoms in schizophrenic patients receiving clozapine: a case series study. Rev Bras Psiquiatr. 2006;28:339-340.
31. Morilak DA, Frazer A. Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioural effects in depression and anxiety disorders. International Journal of Neuropsychopharmacology. 2004;7:193-218.
32. Szabo ST, Blier P. Functional and pharmacological characterization of the modulatory role of serotonin on the firing activity of locus coeruleus norepinephrine neurons. Brain Res. 2001;922:9-20.
33. Parini S, Renoldi G, Battaglia A, Invernizzi RW. Chronic reboxetine desensitizes terminal but not somatodendritic alpha2-adrenoceptors controlling noradrenaline release in the rat dorsal hippocampus. Neuropsychopharmacology. 2005;30:1048-1055.
34. Crews FT, Smith CB. Presynaptic alpha-receptor subsensitivity after long-term antidepressant treatment. Science. 1978;202:322-324.
35. McMillen BA, Warnack W, German DC, Shore PA. Effects of chronic desipramine treatment on rat brain noradrenergic responses to alphaadrenergic drugs. Eur J Pharmacol. 1980;61:239-246.
36. El Mansari M, Guiard BP, Chernoloz O, Ghanbari R, Katz N, Blier P. Relevance of norepinephrine-dopamine interactions in the treatment of major depressive disorder. CNS Neurosci Ther. 2010;16:e1-e17.
37. Arnsten AF, Li BM. Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions. Biol Psychiatry. 2005;57: 1377-1384.